Hologic Completes the Acquisition of Gen-Probe
By LabMedica International staff writers Posted on 06 Aug 2012 |
Hologic (Bedford, MA, USA) has completed the acquisition of Gen-Probe (San Diego, CA, USA) for a net purchase price of USD 3.72 billion.
Gen-Probe is a molecular diagnostics company with services used to diagnose human diseases, screen donated human blood, ensure transplant compatibility, and aid biomedical research.
The acquisition will allow Hologic to expand its growing diagnostics products and services business. Hologic, Inc. is a developer, manufacturer, and supplier of diagnostic products, medical imaging systems, and surgical products. The company operates four core business units focused on breast health, diagnostics, GYN surgical, and skeletal health.
“Gen-Probe is an ideal partner and strategic fit to Hologic’s existing diagnostics business and complements our focus on scaling and diversifying our diagnostics franchise,” Robert A. Cascella, the chief executive of Hologic, said in a statement. “Our combined company will be well positioned globally to capitalize on the fast-growing molecular diagnostics market with an established global infrastructure.”
Related Links:
Hologic
Gen-Probe
Gen-Probe is a molecular diagnostics company with services used to diagnose human diseases, screen donated human blood, ensure transplant compatibility, and aid biomedical research.
The acquisition will allow Hologic to expand its growing diagnostics products and services business. Hologic, Inc. is a developer, manufacturer, and supplier of diagnostic products, medical imaging systems, and surgical products. The company operates four core business units focused on breast health, diagnostics, GYN surgical, and skeletal health.
“Gen-Probe is an ideal partner and strategic fit to Hologic’s existing diagnostics business and complements our focus on scaling and diversifying our diagnostics franchise,” Robert A. Cascella, the chief executive of Hologic, said in a statement. “Our combined company will be well positioned globally to capitalize on the fast-growing molecular diagnostics market with an established global infrastructure.”
Related Links:
Hologic
Gen-Probe
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics